499770-73-9

Usage

Uses

Used in Organic Synthesis:
4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBONYL CHLORIDE is used as a reactive intermediate for the synthesis of various organic compounds due to its carbonyl chloride group, which facilitates the formation of new chemical bonds and the creation of complex molecular structures.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBONYL CHLORIDE is used as a key building block for the development of new drugs. Its unique structure allows for the design and synthesis of novel drug candidates with potential therapeutic applications.
Used in Material Development:
4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBONYL CHLORIDE is also utilized in the development of new materials, where its reactivity and structural properties can contribute to the creation of innovative materials with specific properties for various applications.

InChI:InChI=1/C10H10ClNO2/c1-12-4-5-14-9-6-7(10(11)13)2-3-8(9)12/h2-3,6H,4-5H2,1H3

Upstream product

• 532391-89-2 4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboxylic acid 

Relevant academic research and scientific papers

Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus

A new class of diphenylurea was identified as a novel antibacterial scaffold with an antibacterial spectrum that includes highly resistant staphylococcal isolates, namely methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA & VRSA). Starting with a lead compound 3 that carries an aminoguanidine functionality from one side and a n-butyl moiety on the other ring, several analogues were prepared. Considering the pharmacokinetic parameters as a key factor in structural optimization, the structure-activity-relationships (SARs) at the lipophilic side chain were rigorously examined leading to the discovery of the cycloheptyloxyl analogue 21n as a potential drug-candidate. This compound has several notable advantages over vancomycin and linezolid including rapid killing kinetics against MRSA and the ability to target and reduce the burden of MRSA harboring inside immune cells (macrophages). Furthermore, the potent anti-MRSA activity of 21n was confirmed in?vivo using a Caenorhabditis elegans animal model. The present study provides a foundation for further development of diphenylurea compounds as potential therapeutic agents to address the burgeoning challenge of bacterial resistance to antibiotics.